Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase NA 9Phase 3 4Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Carcinoma, Non-Small-Cell Lung 187Neoplasm Metastasis 150Neoplasms 141Leukemia, Myeloid, Acute 138Colorectal Neoplasms 131Breast Neoplasms 120Melanoma 95Ovarian Neoplasms 93Prostatic Neoplasms 89Recurrence 85Multiple Myeloma 83Lung Neoplasms 78Pancreatic Neoplasms 77Glioblastoma 77Squamous Cell Carcinoma of Head and Neck 75Myelodysplastic Syndromes 66Lymphoma, Non-Hodgkin 65Triple Negative Breast Neoplasms 57Glioma 57Stomach Neoplasms 54Endometrial Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Carcinoma, Renal Cell 49Brain Neoplasms 48Small Cell Lung Carcinoma 47Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Hepatocellular 45Lymphoma, B-Cell 42Lymphoma, Follicular 40Advanced Solid Tumors 40

Interventions

poly ICLC 1exemestane 1Tamoxifen 1Specimen Handling 1Selective Estrogen Receptor Modulators 1Letrozole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Biopsy 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Intraductal, Noninfiltrating × 90 days × Clear all
NCT03317405 2026-05-04

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
32 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07408856 2026-04-08

CAN1012 in Pre-Malignant DCIS and LCIS

Providence Health & Services

Phase 1 Not yet recruiting
24 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT04144023 2026-03-05

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Mayo Clinic

Phase 1 Recruiting
43 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡